可见垂体瘤残余的高泌乳素血症患者停用卡麦角林后的生化缓解
该回顾性队列研究纳入44例经卡麦角林治疗至少12个月、泌乳素正常但仍有可见肿瘤残余的泌乳素瘤患者,停药后33例维持正常泌乳素血症,11例在12-97个月内复发高泌乳素血症。诊断时海绵窦侵犯与复发率增加相关,缓解组治疗6个月后T2信号强度比显著下降(P = .043)。
要点
- 可见肿瘤残余患者停用卡麦角林后部分可维持生化缓解。
- 诊断时海绵窦侵犯可能是不利的缓解预测因素。
- 治疗6个月T2信号强度比显著下降与缓解相关。
核心结论
- 在可见肿瘤残余的泌乳素瘤患者中,诊断时存在海绵窦侵犯可能是停用卡麦角林后生化缓解的不利预测因素。
研究设计与样本
- 回顾性队列研究,2005至2018年间筛选734例接受卡麦角林治疗至少12个月的泌乳素瘤患者,最终纳入44例泌乳素正常、使用最小卡麦角林剂量但仍有可见肿瘤残余并停药的患者。
主要发现
- 44例患者中33例停药后维持正常泌乳素血症,11例在12-97个月内出现高泌乳素血症。
- 复发组初始泌乳素水平和海绵窦侵犯机会更高,两组年龄、性别、最大及残余肿瘤大小和治疗持续时间相似。
- 缓解组卡麦角林治疗6个月后T2信号强度比显著下降(P = .043)。
关键数值与推荐
- 诊断时中位年龄32(18-58)岁,女性占95.45%。
- 中位治疗持续时间32(12-120)个月。
- 复发组停药后至高泌乳素血症的中位时间26(12-97)个月。
- 缓解组治疗6个月后T2信号强度比显著下降,P = .043。
临床怎么用
- 对可见肿瘤残余的泌乳素瘤患者停用卡麦角林前应评估诊断时海绵窦侵犯情况。
- 停药后需监测泌乳素水平,复发可能发生在停药后12-97个月内。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Dopamine agonists (DAs) are the first-line therapy for prolactinomas. Although pituitary tumors often do not completely disappear, discontinuing DAs in patients with no visible tumor on magnetic resonance imaging is advised. OBJECTIVE: To analyze biochemical remission after cabergoline (CAB) withdrawal in patients with visible remnant pituitary tumors. DESIGN: Retrospective cohort study. SETTING: Severance Hospital. SUBJECTS: We identified 734 patients with prolactinomas undergoing CAB therapy for at least 12 months from 2005 to 2018. We selected 44 patients with prolactinomas who discontinued CAB with normal prolactin levels; they were receiving a minimal CAB dose but had visible remnant tumors. RESULTS: Median age at diagnosis was 32 (18-58) years, and most patients were women (95.45%). Median treatment duration was 32 (12-120) months. Of 44 patients, 33 continued to have normoprolactinemia, but 11 patients developed hyperprolactinemia after drug withdrawal within 26 (12-97) months. Age, sex, maximal and remnant tumor size, and treatment duration were similar between the groups. The initial prolactin level and chances of cavernous sinus (CS) invasion were higher in the recurrence group. CS invasion at diagnosis was associated with an increased recurrence rate. Although treatment response did not correlate with the initial and final signal intensity assessments, a significant decrease in T2 intensity ratio after 6 months of CAB therapy was observed in the remission group (P = .043). CONCLUSION: In patients with visible tumors, the presence of CS invasion at diagnosis may be an unfavorable predictor for biochemical remission after CAB discontinuation.
引用
- Kim K, Park YW, Kim D, et al. Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma. J Clin Endocrinol Metab. 2021. PMID: 33079168. doi:10.1210/clinem/dgaa744
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。